Background/Aims: Emerging novel optical imaging techniques with cancer-specific molecular imaging agents offer a powerful and promising platform for cancer detection and resection. White-light cystoscopy and random bladder biopsies remain the most appropriate but nonetheless suboptimal diagnostic technique for bladder cancer, which is associated with high morbidity and recurrence. However, white-light cystoscopy has intrinsic shortcomings.
Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer

Introduction
Optical imaging techniques used for interventional guidance have evolved rapidly in recent years. Likewise, more and more cancer-specific targets have been identified as promising molecular imaging agents. The combination of the advances in both of these areas has permitted powerful and useful alternatives or adjuncts to traditional means of endoscopic cancer detection and resection [1, 2] . White-light endoscopy is the technique primarily used to optically inspect cancers of the gastrointestinal and urinary tracts for subsequent biopsy or resection [3] . However, although it is the gold standard for the diagnosis of some solid tumors, the complete extent of the tumor burden of a local organ can be difficult to confirm on white-light endoscopy alone, particularly for small "satellite" tumors or areas of early lesions that appear flat with unclear boundaries. Inadequate visualization of microtumors on whitelight endoscopy could account for cancer recurrence and progression. However, fluorescent endoscopy with fluorescently labeled molecular probes offers enhanced differentiation between tumors and adjacent normal or benign tissues. Therefore, exploration of molecular imaging agents that can specifically target cancer is of considerable interest.
In 2017, there were an estimated 80, 000 cases of bladder cancer (BC) in the United States, making BC the second most common malignancy of the urinary system [4] . This cancer has high recurrence, up to 50-70% at 5 years for non-muscle-invasive BC (NMIBC) [5] . Because the recurrence rate requires intensive endoscopic surveillance strategies or additional operations, BC management is the most expensive of all solid tumors [6] . Whitelight cystoscopy and random bladder biopsies for pathological diagnosis and local staging remain the most appropriate techniques for the diagnosis and follow-up of BC. Approximately 75% of urinary bladder tumors are superficial NMIBC. For these patients, endoscopic resection followed by intravesical Bacillus Calmette-Guérin (BCG) vaccine or chemotherapy is recommended for definitive treatment, whereas multiple treatments involving radical cystectomy with neoadjuvant chemotherapy is the standard treatment strategy for patients who present or recur with muscle-invasive cancer (stage ≥ T2) [7, 8] . However, white-light cystoscopy has some well-known deficiencies, including inadequate tumor delineation to enable complete resection (especially for carcinoma in situ [CIS] ) and difficult differentiation between inflammation and malignancy [9] .
In recent years, novel molecular imaging technologies used to identify suspicious lesions have sprung up rapidly, such as fluorescence cystoscopy/photodynamic diagnosis, narrow band imaging, and confocal laser endomicroscopy, which aim to address the limitations of white-light cystoscopy and have in vivo feasibility [10] . Blue-light cystoscopy with various photosensitizers, such as hexaminolevulinate hydrochloride (HAL), as a promising adjunct to white-light cystoscopy for enhanced identification and guidance of endoscopic resection takes advantage of the preferential uptake and accumulation of protoporphyrins in neoplastic tissue, which emit a red fluorescence when excited using blue light (360-450 nm wavelengths) [11] . However, there are still limitations to its clinical application. The operators require considerable experience to distinguish false-positive fluorescence from unspecific uptake of protoporphyrins by inflammatory lesions. Additionally, further work showed fewer benefits for tumor detection [10] .
In this study, we aimed to use a cancer-specific imaging agent to develop a targeted molecular imaging strategy to overcome the defects of current visualizing imaging technologies. We considered carbonic anhydrase IX (CAIX) to be of interest after investigating published work [12] [13] [14] [15] and analyzing the data of preliminary experiments. Functionally, CAIX plays an important role in the acid-base homeostasis of tumors under hypoxic conditions due to the deleterious effects of a high rate of glycolytic metabolism in tumor sites. This can lead to more aggressive and treatment-resistant tumor phenotypes [12] . Therefore, the inhibition of CAIX with a relevant antibody could allow the use of an extensive therapeutic strategy to suppress tumor growth and reduce metastasis in cancer patients. Previous studies demonstrated that CAIX is an ideal biomarker for tracking the recurrence, progression, and overall survival of BC patients [13] [14] [15] . Not only is CAIX constitutively expressed in most BCs, but it is also expressed differentially in noninvasive versus invasive tumors, in low-grade versus high-grade BC, and in primary tumors versus metastases [13] [14] [15] . Considering the differential expression and function of CAIX, we developed and evaluated a fluorescently labeled antibody (anti-CAIX) as an intravesical imaging agent for optimizing the integration of novel imaging technologies into clinical practice.
Materials and Methods
Human tissue samples
Human BC tissues were provided by the Fourth Affiliated Hospital of Harbin Medical University after approval was obtained from the university's Ethics Committee on the Use of Human Samples. The tissues were obtained from 8 individuals undergoing radical cystectomy. The sampled tissues were immediately snap-frozen in liquid nitrogen and stored at -80°C.
Identification of differentially expressed genes associated with BC
Based on the edgeR algorithm, we identified differentially expressed genes (DEGs) with mRNA expression profiles. The Benjamini-Hochberg multiple testing method was used to adjust the p value (false discovery rate [FDR] ). The thresholds were FDR < 0.01 and |log2FC| > 2 (FC, fold change). We considered the genes satisfying these criteria to be DEGs.
Real-time PCR
Total RNA was extracted from the human tissues and cell lines using Trizol (Invitrogen, Carlsbad, California, USA). The levels of CAIX mRNA were quantified using the mirVana quantitative real-time PCR (qRT-PCR) miRNA Detection Kit (Ambion, Carlsbad, California, USA) in conjunction with real-time PCR with SYBR Green I (Applied Biosystems, Carlsbad, California, USA) according to the manufacturer's instructions. The qRT-PCR was performed on an ABI Prism® 7500 fast thermocycler (Applied Biosystems) for 40 cycles. The following CAIX primers were used for PCR detection: 5'-GGGAGGTGGTCGCTGTAAAA-3' (forward), 5'-ACCAGCACTGTAGCACACTC-3' (reverse). The relative expression levels of CAIX were calculated through normalization to their internal control (glyceraldehyde 3-phosphate dehydrogenase [GAPDH] ). The relative expression intensity values were calculated as 2-ΔΔCt.
Immunohistochemical staining
Tissue samples were fixed in 4% formaldehyde and embedded in paraffin. For the immunohistochemical study, the deparaffinized tissue sections were incubated with affinity-purified antibodies against CAIX (1:200) as the primary antibody. Immunoperoxidase staining was applied to the specimens using the streptavidin-biotin-peroxidase complex. The samples were classified as CAIX-negative or CAIX-positive according to whether the percentage of CAIX-positive cells was <10% or >10%, respectively. And all the IHC slides were analyzed by Image Pro Plus 6.0 through calculating the integrated optical density (IOD) value of staining parts CAIX fluorescent imaging by blue-light cystoscopy Anti-CAIX antibody was labeled with Qdot625 (excitation, 405 nm; emission, 625 nm; Life Technologies) by amine-thiol cross-linking per the manufacturer's protocol. The labeled antibody (15 nM in 50 mL saline) was instilled into fresh intact bladders and incubated for 1 h. For imaging, all of the bladder specimens were treated with a clinical blue-light cystoscopy system (Karl Storz) that is able to shift between standard white light and blue light for fluorescence imaging (375 to 440 nm) and detection of red light above 610 nm [11] . 
Statistical analysis
All data are presented as the mean ± standard error of the mean. A t-test using Bonferroni correction or a Dunnett's test was used to evaluate the significance of the differences between the individual means. Otherwise, the data were compared by a Student's t-test. A two-tailed difference with p < 0.05 was considered statistically significant. For the diagnostic accuracy of CAIX-targeted blue light cystoscopy imaging, sensitivity was calculated as TP/(TP + FN), and specificity as TN/(TN + FP), (TP: true positive, FN: false negative, TN: true negative, and FP: false positive). 2-tailed Spearman's correlation coefficient method was used to assess correlation between two parameters. The data were analyzed using GraphPad Prism 7.0.
Results
CAIX expression
Some studies have reported that CAIX expression is markedly higher in urine samples from BC patients compared with controls [14, 15] . In this context, we hypothesized that CAIX expression would be significantly different between BC and normal tissue specimens. Therefore, we designed a scientific and systematic validation process to explore the differential expression of CAIX between BC tissue and normal bladder tissue. We first focused on the analysis of data from The Cancer Genome Atlas (TCGA) and performed a wholegenome expression analysis in 410 tumor tissues and 19 normal tissues from patients with BC using the R package edgeR. The Benjamini-Hochberg multiple testing method was used to correct the p values.
Using the criteria (|log2FC|>2, FDR<0.01), 1156 DEGs were assigned to the BC group. About two-fifths of the total DEGs were overexpressed in cancer tissue (446 genes, 39%
[cancer] > [normal]), whereas the others exhibited reduced expression (710 genes, 61%
[normal] > [cancer]) (Fig. 1A) . We next analyzed the expression of CAIX in the same data set. CAIX expression was significantly higher in the BC specimens than in normal tissue (Fig. 1B) . To further confirm the differential expression of CAIX, 21 matching samples of BC and adjacent normal tissue were obtained from patients who underwent cystectomy or transurethral resection of the bladder (TURB). All of the associated clinical and pathologic information were also prospectively collected from the BC patients (Table 1) . Total RNA was isolated from all of the selected fresh snap-frozen specimens. The expression of CAIX was analyzed by qRT-PCR after reverse transcription. A 3.9-fold increase in CAIX mRNA expression was detected in the BC tissue compared with the control (p < 0.01) (Fig. 1B) .
To assess the expression of CAIX, 18 paraffinembedded BC specimens covering five pathological subtypes (noninvasive papillary urothelial carcinoma, urothelial carcinoma, papillary urothelial carcinoma with squamous differentiation, CIS, and adenocarcinoma) were subjected to an immunohistochemical assay with affinitypurified antibodies against CAIX. In addition, 9 specimens of benign bladder tissue including normal mucosa, squamous metaplasia, and inflammation were also considered. BC specimens classified in four pathological subtypes presented a variety of positive staining intensities, whereas all the benign specimens showed negative ( Fig. 2A-I ). And it was demonstrated differential expression of CAIX between bladder cancer and benign bladder tissues (p<0.01, Fig 2J) . Remarkably, even high grade papillary UCs that had the lowest level CAIX staining in all types of bladder cancer showed significant increase In order from the left to right: normal bladder mucosa, squamous metaplasia, bladder inflammation, lowgrade noninvasive papillary urothelial carcinoma, high-grade noninvasive papillary urothelial carcinoma, urothelial carcinoma, papillary urothelial carcinoma with squamous differentiation, CIS, adenocarcinoma. (Low-grade noninvasive papillary UC vs normal bladder mucosa and bladder inflammation, p<0.01). Magnification: ×100. Scale bars, 100 μm. in CAIX expression compared with the adjacent normal bladder tissues. Consistent with our findings, an article published in European Urology [14] has shed further light on the significant difference in CAIX expression between paired urine and tumor specimens. All of the data suggest the promising value of CAIX as a targeted molecular imaging agent for BC.
Application of CAIX to in vivo endoscopy molecular imaging
Blue-light cystoscopy is characterized by the combination of white-light cystoscopy and a blue-light fluorescence-exciting system, which allow the operator to switch dynamically between them. To evaluate the value of anti-CAIX as a BC imaging agent in vivo, we developed an endoscopic molecular imaging protocol for the human bladder. Considering the possibility of latent toxicity and unexpected adverse events in associated with in vivo examination of the bladder, we obtained fresh, intact bladder from patients with high-stage muscle-invasive BC or multiple high-risk NMIBC who underwent radical cystectomy (n = 8). The clinicopathologic characteristics of the patients with BC are shown in Table 2 . Next, we linked the monoclonal CAIX antibody with a fluorescent molecule (Qdot625) and intravesically instilled the labeled anti-CAIX via a catheter. After antibody binding for one hour, the excess antibody was removed by irrigation of the bladder with normal saline. The bladders coated with fluorescent-labeled antibody were imaged with blue-light cystoscopy.
BC specificity by targeting CAIX
To clarify whether the pink fluorescence emitted by cancer lesions is attributable to the cancer-specific binding of anti-CAIX-Qdot625, we first incubated a single bladder with Qdot625-labeled isotype control (IgG-Qdot625). After one hour for binding the bladder was voided and washed. We expected that there would be no pink fluorescence on the whole bladder mucosa regardless of the presence of cancerous or normal tissue under blue-light cystoscopy. Then, we reincubated the bladder with Qdot625-labeled anti-CAIX for one hour and obtained intravesical images of the bladder using cystoscopy. Observation under bluelight cystoscopy revealed that there was pink fluorescence on the mucosae with malignant features, but not on normal mucosae, indicating CAIX specificity. Subsequent histopathology of biopsy tissue showed that the lesion binding the anti-CAIX-Qdot625 contained papillary urothelial carcinoma, whereas the region without anti-CAIX-Qdot625 binding contained normal urothelium (Fig. 3A) .
Diagnostic accuracy of CAIX-targeted imaging
To assess the diagnostic value of the novel fluorescent-labeled agent, we performed cystoscopy in all of the excised bladders (n = 8). White-and blue-light images were obtained of benign and cancerous regions after incubation with anti-CAIX-Qdot625 (Fig. 3B&C) . In total, 57 biopsies, including bladder tumor-appearing areas, flat suspicious lesions, and normal bladder mucosa, were examined under white-light cystoscopy, and all fluorescent sites were viewed under blue-light cystoscopy (Table 3&4) . Furthermore, all biopsies were verified by histopathological diagnosis. The malignant pathological outcomes included noninvasive papillary urothelial carcinoma (low grade and high grade), CIS, and infiltrating urothelial carcinoma, whereas the benign outcomes were inflammatory tissue and normal urothelium. biopsies) and carcinoma in situ (1 biopsy) (3D). The fluorescent graphs were quantified by mean densities (IOD/Area) of sustaining pink parts shown in Fig. 3C . From the 32 benign tissues validated by pathology, 30 biopsies were true negative without detectable anti-CAIX binding, giving a specificity of 93.75%. However, the 2 misdiagnosed biopsy that appeared to be benign under blue-light cystoscopy were pathologically confirmed as normal urothelium and inflammatory lesion (1 each).
It is easy to differentiate papillary urothelial carcinoma from normal urothelium by conventional white-light cystoscopy. Noninvasive papillary urothelial carcinoma is the most common type of BC, accounting for 75% of BCs. Notably, 12 of the 14 biopsies pathologically diagnosed with this condition showed the pink fluorescence of anti-CAIX-Qdot625. Similarly, 5 of the 5 biopsies with pathologically confirmed infiltrating urothelial carcinoma also presented positive anti-CAIX-Qdot625 signal. CIS generally appears as flat lesions that are hardly visible on ultrasound, computed tomography, or magnetic resonance imaging. These lesions have high risk of progression to muscle-invasive cancer and recurrence. Even when comprehensively examined by whitelight cystoscopy, some CISs still cannot be distinguished from the normal urothelium due to its high resemblance to normal mucosa and its indistinct margins. For the group of CISs, 3 of the 4 were detected by blue-light cystoscopy through anti-CAIX-Qdot625 imaging. Notably, all CIS biopsies showed normal appearance under white-light cystoscopy and were overlooked but could be seen when imaged under blue light.
For suspicious benign lesions and normal urothelium under white light, 5 of the 6 inflammatory lesions without anti-CAIX-Qdot625 binding were classified in the true negative group. Except for one site of the normal bladder mucosa that showed a slight fluorescent signal, the remaining 25 sites displayed only blue background and vascular venation. Although inflammation is likely to bind anti-CAIX-Qdot625 due to denudation of the urothelium or lymphocyte infiltration, 96.15% of these benign biopsies were true negative for anti-CAIXQdot625 binding (Table 3 ). And ROC curve was plotted to illustrate the diagnostic accuracy of the two imaging methods for identifying bladder cancer (Fig 4A) . We further detected CAIX expression of 22 tumor biopsies which were found by blue-light cystoscopy (Fig 4B) and divided them with three groups according to expression level (low, median, and high expression, 33% and 66% as cutoff point of the expression data in ascending order) (Fig 4C) . And after analyzing the mean density of each corresponding graph we found the differences of mean density between three groups also were statistically significant (low vs median, p＜0.05, low vs high, p＜0.01) (Fig 4D) . By using Spearman's correlation coefficient method, we got positive correlation between CAIX expression and fluorescent intensity under bluelight cystoscopy (r=0.886，p＜0.01) (Fig 4E) . In summary, the anti-CAⅨ-Qdot625 guided blue-light cystoscopy showed the higher sensitivity compared with white-light cystoscopy imaging conferred more precise detection of small lesions.
Discussion
Significant attention has been paid to fluorescence guidance of the diagnosis and surgical resection of BC due to potential improvements in sensitivity and specificity and the longterm benefits for recurrence and progression after resection. In this study, we endeavored to develop a novel endoscopic imaging system involving blue-light cystoscopy by combining a fluorescent imaging agent that targeted CAIX, a surface protein with differential expression between cancer cells and normal urothelium. Our work demonstrated that the high expression of CAIX in BC makes it a viable imaging target. We successfully developed a CAIX antibody labeled with a fluorescent tag, anti-CAIX-Qdot625, for intravesical administration. Detection of anti-CAIX bound to the luminal surface of biopsy tissue from tumors but not normal tissue supports the specific targeting of CAIX via intravesical administration of the antibody. In addition, we used a whole-bladder imaging strategy to simulate a future in vivo endoscopic application and facilitate clinical translation of the anti-CAIX molecular imaging in order to improve BC detection and transurethral resection quality.
Cancer cells tend to grow under hypoxic conditions and shift their metabolism from a high level of glycolysis to lactic acid fermentation in the cytoplasm [16] . CAIX, as a transporter of CO 2 and hydrogen carbonate, is believed to export and extrude H + out of the cytosol to maintain the intracellular physiological pH homeostasis. In addition, the expression level of CAIX is significantly related to the hypoxic status [17] . Extensive research has shown that an elevated expression of CAIX is often related to poor prognosis in many malignancies, including renal cell carcinoma, breast, cervical, and non-small cell lung cancer, as well as BC [18] [19] [20] [21] . In renal cell carcinoma, expression of CAIX is controlled by the lack of or an aberration in von Hippel-Lindau (VHL), a tumor-suppressing gene, and nearly all forms of clear cell renal cell carcinoma express high levels of CAIX, which is downregulated in normal kidney tissue [22] . Thus, CAIX is a tumor-associated antigen cancer with diagnostic utility [23] . Previously, the advent of new photosensitizers led to considerable attention to blue-light cystoscopy amid the possibility of numerous applications. In addition, endoscopic molecular imaging with photosensitive protoporphyrin analogues takes advantage of the selective accumulation abilities of rapidly proliferating cells. Most clinical studies of photosensitive protoporphyrin analogues are based on 5-ALA [24] , although another analogue, HAL, is more promising, given that it has been approved for clinical use in both Europe and the United States [11] . Although the approved photodynamic diagnosis based on protoporphyrins such as hexaminolevulinate shares the advantages of an improved detection of NMIBC beyond that achieved with white-light cystoscopy, there are several inherent and technical deficiencies that restrict the extensive clinical application of photodynamic diagnosis with protoporphyrin. Up to a 30% false-positive rate has been reported, particularly with prior BCG treatment or chemotherapy that lead to overuse of bladder biopsies due to low surgeon experience in the learning period [25] . Other possible reasons for false-positive findings include autofluorescence, which is caused by activation of the endogenous fluorescence in response to the blue light and tangential imaging [9, 26] . Hexaminolevulinate is approved for single administration on account of potential drug hypersensitivity with repeat exposure. Other technical limitations include a decreased optical management with incomplete hemostasis and a photobleaching effect causing loss of fluorescence [27] . Undeniably, wide-field fluorescence imaging of CAIX offers potential advantages over the currently approved blue-light cystoscopy with protoporphyrin.
Our results showed that anti-CAIX-Qdot625 binds to papillary urothelial carcinoma regardless of grade and the presence of infiltrating urothelial carcinoma. Anti-CAIX fluorescent imaging also overcame the diagnostic limitation of white-light cystoscopy, competently identifying CIS, which is missed by white-light cystoscopy. BCG is still the most effective intravesical treatment to decrease both the progression and recurrence of high-risk nonmuscle-invasive bladder cancers, including CIS [28, 29] . In addition to BCG, a growing number of studies have investigated alternative intravesical agents with equivalent efficacy to BCG [30] . We believe that CAIX imaging may improve CIS identification and better stratify patients who would benefit most from BCG treatment while evaluating the treatment response to BCG. In further study, more pathological types of BC should be included, such as papillary urothelial carcinoma with squamous differentiation, micropapillary carcinoma, and adenocarcinoma. All of these pathological types present infrequently in patients with BC and thus require long-time specimen collection periods.
The bladder is a hollow organ with an established intravesical route to receive and reserve pharmacological agents including live attenuated vaccines (e.g., BCG) and highdose chemotherapy (e.g., gemcitabine) without significant systemic absorption. Its unique physiological and anatomic properties allow intravesical administration, which minimizes potential systemic toxicity from the imaging agent, making the bladder an attractive target organ for endoscopic molecular imaging and image-guided surgery. The CAIX antibody used in our study is a mouse monoclonal antibody and unlikely to be suitable for application to humans due to the risk of an allergic response caused by heterogeneous serum. However, a humanized, compatible manufacturing practice-grade monoclonal CAIX antibody is currently being studied for therapeutic use. A novel human anti-CAIX monoclonal antibody has therapeutic potential in the unmet medical need of the specific elimination of highlyexpressed CAIX renal carcinoma cells [31] . In addition, the chimeric antibody girentuximab has been widely tested in clinical trials for administration both alone and in combination with multiple drugs, including radioisotopes, cytokines, and chimeric antigen receptor (CAR) T cell therapy [32, 33] . If the CAIX antibody is found to be safe without toxic side-effects in vivo, it could be labeled with a fluorescent molecule for optical molecular imaging. Even if this CAIX antibody is not suitable for systemic administration, the intravesical mode allows a safe alternative for diagnosis and treatment.
For the clinical translation of a Qdot625-labeled CAIX antibody, additional work is required to determine the stability and safety profile of intravesical anti-CAIX before human trials. Quantum dots (Qdots), which are semiconductor nanocrystals ranging from 2 to 10 nm in diameter, are promising alternatives to organic dyes, which emit fluorescence depending on their particle size [34] . Despite the latent toxicity of the heavy metal core in Qdots, considerable effort is being expended to improve their biocompatibility and stability, given the advantages of Qdots, including stronger fluorescence intensity and resistance to photobleaching upon excitation.
Although our study indicated that CAIX as an imaging target is an important predictor of overall survival and that CAIX-targeted imaging allows detection of a wide variety of BC types, there are other putative intrinsic markers of hypoxia under regulation by hypoxiainducible factor-1 (HIF-1). Studies have indicated that HIF-1α fused to firefly luciferase can be used to dynamically monitor cardiomyocyte oxygenation in living heart muscle samples [35] . In addition to HIF-1α, studies have shown that GLUT1 expression is absent from normal bladder mucosa but is present in malignant bladder mucosa, with greater expression in muscle-invasive tumors compared with superficial BC [36] . Li et al. [37] reported that miR-218 increases the sensitivity of BC to cisplatin, an effect that can be ameliorated by targeting GLUT1, indicating its potential therapeutic value. CD44, a member of the cell surface glycoprotein family, functions in cell-cell and cell-matrix interactions, chiefly in epithelial cells [38] . CD44 and its variants are closely related to aggressive progression and poor patient prognosis in many types of cancer [39, 40] . BCs progressively lose CD44 proteins as they penetrate deeper and become less differentiated. In patients lacking CD44v6 in BC tissue, there is a 2.3-fold increased risk of recurrence (95% confidence interval, 1.28-4.08) [41] . Pan et al. [42] reported CD47 as a target for blue-light cystoscopy imaging of BC. The study found a sensitivity of 82.9% and a specificity of 90.5% for CD47-targeted imaging of BC. Although several promising candidate markers such as CAIX have been identified, there are few potent molecular biomarkers with widely proven utility for endoscopic molecular imaging in general and for improving clinical outcomes. Identification of molecular markers that better classify tumors with multiple tumor characteristics such as the pathological stage or response to specific treatment may help in the development of more refined imaging detection tools for the selection of precise and individualized BC therapies.
Our research sheds new light on the identification and validation of molecular imaging targets, with CAIX serving as a cancer-specific imaging agent for BC and likely for other epithelial cancers. Our intact-organ imaging approach takes advantage of the ease of accessing the well-established intravesical route of the bladder for drug administration. This imaging system represents a potentially powerful way to facilitate the endoscopic detection of cancer and its resection in the urinary bladder or other hollow viscera, contributing to better overall survival due to less recurrence. Together, our study offers sufficient evidence for CAIX as a BC imaging target with promising prospects for clinical translation.
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